Because We're Worth It | GenomeWeb

Genentech finally came through with its long-expected rejection of Roche's acquisition bid, saying that the asking price "substantially undervalues the company," according to this story in the New York Times. Analysts predict that the companies will continue to negotiate, and that Roche will raise the offer from its original $43.7 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.